Patient baseline characteristics and prior therapy
| Variable . | Number (%) . |
|---|---|
| Gender, male | 14 (72.7) |
| Age in years, median (range) | 59 (29-76) |
| Disease status | |
| Relapsed | 10 (52.6) |
| Refractory | 8 (42.1) |
| Other* | 1 (5.3) |
| ELN cytogenetic risk | |
| Favorable | 1 (5.3) |
| Intermediate | 17 (89.5) |
| Adverse | 1 (5.3) |
| Peripheral WBC ×109 cells/L, median (range) | 4.8 (<0.3-79.1) |
| Peripheral myeloblast %, median (range) | 17.5 (0-98) |
| Bone marrow myeloblast %, median (range) | 52.5 (2-94) |
| FLT3 mutation status | |
| ITD positive | 17 (89.5) |
| Both ITD and TKD positive | 1 (4.5) |
| TKD positive | 1 (4.5) |
| Bone marrow transplant | |
| Pre | 11 (57.9) |
| Post | 8 (42.1) |
| Prior therapy | |
| Newly diagnosed | |
| 7 + 3 | 1 (5.3) |
| 7 + 3 and/or HiDAC + midostaurin | 14 (73.7) |
| BI 836858 + azacytidine | 1 (5.3) |
| Entospletinib + azacytidine | 1 (5.3) |
| Enasidenib | 1 (5.3) |
| Unknown | 1 (5.3) |
| Relapsed/refractory disease (before gilteritinib) | |
| Pacritinib, selinexor + mitoxantrone/etoposide/cytarabine, sorafenib | 1 (5.3) |
| Venetoclax + azacytidine, AZD5991 | 1 (5.3) |
| FLAG + HMA | 1 (5.3) |
| Variable . | Number (%) . |
|---|---|
| Gender, male | 14 (72.7) |
| Age in years, median (range) | 59 (29-76) |
| Disease status | |
| Relapsed | 10 (52.6) |
| Refractory | 8 (42.1) |
| Other* | 1 (5.3) |
| ELN cytogenetic risk | |
| Favorable | 1 (5.3) |
| Intermediate | 17 (89.5) |
| Adverse | 1 (5.3) |
| Peripheral WBC ×109 cells/L, median (range) | 4.8 (<0.3-79.1) |
| Peripheral myeloblast %, median (range) | 17.5 (0-98) |
| Bone marrow myeloblast %, median (range) | 52.5 (2-94) |
| FLT3 mutation status | |
| ITD positive | 17 (89.5) |
| Both ITD and TKD positive | 1 (4.5) |
| TKD positive | 1 (4.5) |
| Bone marrow transplant | |
| Pre | 11 (57.9) |
| Post | 8 (42.1) |
| Prior therapy | |
| Newly diagnosed | |
| 7 + 3 | 1 (5.3) |
| 7 + 3 and/or HiDAC + midostaurin | 14 (73.7) |
| BI 836858 + azacytidine | 1 (5.3) |
| Entospletinib + azacytidine | 1 (5.3) |
| Enasidenib | 1 (5.3) |
| Unknown | 1 (5.3) |
| Relapsed/refractory disease (before gilteritinib) | |
| Pacritinib, selinexor + mitoxantrone/etoposide/cytarabine, sorafenib | 1 (5.3) |
| Venetoclax + azacytidine, AZD5991 | 1 (5.3) |
| FLAG + HMA | 1 (5.3) |
7 + 3, cytarabine continuously for 7 days with an anthracycline days 1 to 3; FLAG, fludarabine with HiDAC, idarubicin, and granulocyte-colony stimulating factor; HiDAC, high-dose cytarabine; HMA, hypomethylating agent.
Gilteritinib treatment post-transplant.